Novavax (NVAX) Accumulated Expenses (2010 - 2026)

Novavax's Accumulated Expenses history runs 17 years deep, the most recent figure standing at $103.0 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 22.05% year-over-year to $103.0 million in Q1 2026; TTM through Mar 2026 was $103.0 million, a 22.05% decrease from a year earlier, with the FY2025 full-year figure at $107.2 million, down 49.25% from the prior year.
• Accumulated Expenses eased to $103.0 million in Q1 2026 per NVAX's latest filing, from $107.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $591.2 million in Q4 2022 and bottomed at $86.7 million in Q2 2025.
• The 5-year median for Accumulated Expenses is $257.4 million (2024), against an average of $315.4 million.
• Across the five-year window, Accumulated Expenses jumped 276.74% in 2022 and plunged 65.27% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $591.2 million in 2022, then tumbled by 33.24% to $394.7 million in 2023, then sank by 46.5% to $211.2 million in 2024, then sank by 49.25% to $107.2 million in 2025, then decreased by 3.86% to $103.0 million in 2026.
• Per Business Quant, the three latest NVAX Accumulated Expenses figures stand at $103.0 million (Q1 2026), $107.2 million (Q4 2025), and $115.6 million (Q3 2025).